For many drug developers and clinical operations leaders in the biotech and pharmaceutical industry, the question, discussion, and decision of whether to fully adopt decentralized and digital clinical trials has been ongoing since the Covid pandemic. Topics such as the upfront costs, cost savings and efficiencies compared to traditional studies, and the return on investment (ROI) continue to circulate. For many, the final verdict is still under consideration. A recent study conducted by the Tufts Center for the Study of Drug Development (CSDD) evaluated the cost benefits and value of utilizing digital technology in non- traditional clinical trials, i.e. virtual and decentralized trials using fewer to no sites. Tufts estimated the total cost to develop and commercialize a new asset as $2.6 billion. The analysis resulted in a number of benefits that will help drive the decision towards utilizing digital technology in decentralized clinical trials…

Download our complimentary white paper to learn more